LL-37 as a therapeutic target for late stage prostate cancer

Prostate

Volumn 71, Issue 6, 2011, Pages 659-670

  Hensel, Jonathan A ^a   Chanda, Diptiman ^a   Kumar, Sanjay ^a   Sawant, Anandi ^a   Grizzle, William E ^a   Siegal, Gene P ^a   Ponnazhagan, Selvarangan ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

androgen independent; angiogenesis; CRAMP; metastasis; proliferation

Indexed keywords

CASPASE 3; CATHELICIDIN ANTIMICROBIAL PEPTIDE; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CD31 ANTIGEN; COLLAGENASE; GELATINASE B; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEPTIDE DERIVATIVE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER STAGING; CARCINOGENICITY; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR VOLUME;

ADENOCARCINOMA; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; CATHELICIDINS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; NEOPLASMS, HORMONE-DEPENDENT; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, NEOPLASM;

EID: 79952396539     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21282     Document Type: Article

References (41)

1. Gudmundsson GH, Agerberth B, Odeberg J, Bergman T, Olsson B, Salcedo R,. The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. Eur J Biochem 1996; 238 (2): 325-332. (Pubitemid 26188246)
2. Zaiou M, Gallo RL,. Cathelicidins, essential gene-encoded mammalian antibiotics. J Mol Med 2002; 80 (9): 549-561.
3. Turner J, Cho Y, Dinh NN, Waring AJ, Lehrer RI,. Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob Agents Chemother 1998; 42 (9): 2206-2214. (Pubitemid 28420351)
4. Zanetti M, Gennaro R, Romeo D,. Cathelicidins: A novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett 1995; 374 (1): 1-5.
5. Larrick JW, Hirata M, Zheng H, Zhong J, Bolin D, Cavaillon JM, Warren HS, Wright SC,. A novel granulocyte-derived peptide with lipopolysaccharide- neutralizing activity. J. Immunol 1994; 152 (1): 231-240.
6. Durr UH, Sudheendra US, Ramamoorthy A,. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta 2006; 1758 (9): 1408-1425. (Pubitemid 44436081)
7. Carretero M, Escámez MJ, García M, Duarte B, Holguín A, Retamosa L, Jorcano JL, Río MD, Larcher F,. In vitro and in vivo wound healing-promoting activities of human cathelicidin LL-37. J Invest Dermatol 2008; 128 (1): 223-236. (Pubitemid 350249392)
8. Shaykhiev R, Beisswenger C, Kändler K, Senske J, Püchner A, Damm T, Behr J, Bals R,. Human endogenous antibiotic LL-37 stimulates airway epithelial cell proliferation and wound closure. Am J Physiol Lung Cell Mol Physiol 2005; 289: L842-L848. (Pubitemid 41504416)
9. Heilborn JD, Nilsson MF, Kratz G, Weber G, Sorensen O, Borregaard N,. The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J Invest Dermatol 2003; 120 (3): 379-389. (Pubitemid 36298423)
10. Koczulla R, von Degenfeld G, Kupatt C, Krötz F, Zahler S, Gloe T, Issbrücker K, Unterberger P, Zaiou M, Lebherz C, Karl A, Raake P, Pfosser A, Boekstegers P, Welsch U, Hiemstra PS, Vogelmeier C, Gallo RL, Clauss M, Bals R,. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest 2003; 111 (11): 1665-1672. (Pubitemid 38057748)
11. Tokumaru S, Sayama K, Shirakata Y, Komatsuzawa H, Ouhara K, Hanakawa Y, Yahata Y, Dai X, Tohyama M, Nagai H, Yang L, Higashiyama S, Yoshimura A, Sugai M, Hashimoto K,. Induction of keratinocyte migration via transactivation of the epidermal growth factor receptor by the antimicrobial peptide LL-37. J Immunol 2005; 175 (7): 4662-4668. (Pubitemid 41362007)
12. Chamorro CI, Weber G, Gronberg A, Pivarci A, Stahle M,. The human antimocrobial peptide LL-37 suppresses apoptosis in keratinocytes. J Invest Derm 2009; 129: 937-944.
13. Hanahan D, Weinberg RA,. The hallmarks of cancer. Cell 2000; 100 (1): 57-70. (Pubitemid 30046295)
14. Coffelt SB, Waterman RS, Florez L, Höner zu, Bentrup K, Zwezdaryk KJ, Tomchuck SL, LaMarca HL, Danka ES, Morris CA, Scandurro AB,. Ovarian cancers overexpress the antimicrobial protein hCAP-18 and its derivative LL-37 increases ovarian cancer cell proliferation and invasion. Int J Cancer 2008; 122 (5): 1030-1039. (Pubitemid 351214000)
15. Heilborn JD, Nilsson MF, Jimenez CI, Sandstedt B, Borregaard N, Tham E, Sørensen OE, Weber G, Ståhle M,. Antimicrobial protein hCAP18/LL-37 is highly expressed in breast cancer and is a putative growth factor for epithelial cells. Int J Cancer 2005; 114 (5): 713-719. (Pubitemid 40344432)
16. von Haussen J, Koczulla R, Shaykhiev R, Herr C, Pinkenburg O, Reimer D, Wiewrodt R, Biesterfeld S, Aigner A, Czubayko F, Bals R,. The host defence peptide LL-37/hCAP-18 is a growth factor for lung cancer cells. Lung Cancer 2008; 59 (1): 12-23.
17. Weber G, Chamorro CI, Granath F, Liljegren A, Zreika S, Saidak Z, Sandstedt B, Rotstein S, Mentaverri R, Sánchez F, Pivarcsi A, Ståhle M,. Human antimicrobial protein hCAP18/LL-37 promotes a metastatic phenotype in breast cancer. Breast Cancer Res 2009; 11 (1): R6.
18. Sørensen OE, Follin P, Johnsen AH, Calafat J, Tjabringa GS, Hiemstra PS, Borregaard N,. Human cathelicidin, hCAP-18 is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 2001; 97 (12): 3951-3959.
19. Yang D, Chen Q, Schmidt AP, Anderson GM, Wang JM, Wooters J, Oppenheim JJ, Chertov O,. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med 2000; 192 (7): 1069-1074.
20. Tjabringa SG, Ninaber DK, Drijfhout JW, Rabe KF, Hiemstra PS,. Human cathelicidin LL-37 is a chemoattractant for eosinophils and neutrophils that acts via formyl-peptide receptors. Int Arch Allergy Immunol 2006; 140 (2): 103-112. (Pubitemid 43725804)
21. Kurosaka K, Chen Q, Yarovinsky F, Oppenheim JJ, Yang D,. Mouse cathelin-related antimicrobial peptide chemoattracts leukocytes using formyl peptide receptor-like 1/mouse formyl peptide receptor-like 2 as the receptor and acts as an immune adjuvant. J Immunol 2005; 174 (10): 6257-6265. (Pubitemid 40663818)
22. Chromek M, Slamová Z, Bergman P, Kovács L, Podracká L, Ehrén I, Hökfelt T, Gudmundsson GH, Gallo RL, Agerberth B, Brauner A,. The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. Nat Med 2006; 12 (6): 636-641. (Pubitemid 43865231)
23. Gallo RL, Kim KJ, Bernfield M, Kozak CA, Zanetti M, Merluzzi L, Gennaro R,. Identification of CRAMP, a cathelin-related antimicrobial peptide expressed in the embryonic and adult mouse. J Biol Chem 1997; 272 (20): 13088-13093. (Pubitemid 27216731)
24. Pestonjamasp VK, Huttner KH, Gallo RL,. Processing site and gene structure for the murine antimicrobial peptide CRAMP. Peptides 2001; 22 (10): 1643-1650. (Pubitemid 32918243)
25. Yu K, Park K, Kim Y, Kang SW, Shin SY, Hahm KS,. Solution structure of a cathelicidin-derived antimicrobial peptide, CRAMP as determined by NMR spectroscopy. J Pept Res 2002; 60: 1-9. (Pubitemid 34680828)
26. Shah RB,. Current perspectives on the Gleason grading of prostate cancer. Arch Pathol Lab Med 2009; 133 (11): 1810-1816.
27. Hurwitz AA, Foster BA, Allison JP, Greenberg NM, Kwon ED,. The TRAMP mouse as a model for prostate cancer. Curr Protocol Immunol 2001; 20.5.1-20.5.23.
28. Tuschl TS, Elbashir S, Harborth J, Weber K,. The siRNA user guide. 2003.
29. Wainstein MA, He F, Robinson D, Kung HJ, Schwartz S, Giaconia JM, Edgehouse NL, Pretlow TP, Bodner DR, Kursh ED, Resnick MI, Seftel A, Pretlow TG,. CW R22: Androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res 1994; 54 (23): 6049-6052. (Pubitemid 24378626)
30. Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM,. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 1997; 57 (16): 3325-3330. (Pubitemid 27355467)
31. Jemal A, Siegal R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics. CA Cancer J Clin 2009; 59 (4): 225-249.
32. Sandgren S, Wittrup A, Cheng F, Jönsson M, Eklund E, Busch S, Belting M,. The human antimicrobial peptide LL-37 transfers extracellular DNA plasmid to the nuclear compartment of mamamalian cells via lipid rafts and proteoglycan-dependent endocytosis. J Biol Chem 2004; 279 (17): 17951-17956. (Pubitemid 38568102)
33. Aragon-Ching JB, Dahut WL,. VEGF inhibitors and prostate cancer therapy. Curr Mol Pharmacol 2009; 2 (2): 161-168.
34. Coffelt SB, Tomchuck SL, Zwezdaryk KJ, Danka ES, Scandurro AB,. Leucine leucine-37 uses formyl peptide receptor-like 1 to activate signal transduction pathways, stimulate oncogenic gene expression, and enhance the invasiveness of ovarian cancer cells. Mol Cancer Res 2009; 7 (6): 907-915.
35. Bowdish DM, Davidson DJ, Speert DP, Hancock RE,. The human cationic peptide LL-37 induces activation of the extracellular signal-regulated kinase and p38 kinase pathways in primary human monocytes. J Immunol 2004; 172 (6): 3758-3765. (Pubitemid 38337960)
36. Dimmeler S, Zeiher AM,. Akt takes center stage in angiogenesis signaling. Circ Res 2000; 86: 4-5. (Pubitemid 30044160)
37. Wu LW, Mayo LD, Dunbar JD, Kessler KM, Baerwald MR, Jaffe EA, Wang D, Warren RS, Donner DB,. Utilization of distinct signaling pathways by receptors for vascular endothelial cell growth factor and other mitogens in the induction of endothelial cell proliferation. J Biol Chem 2000; 275 (7): 5096-5103. (Pubitemid 30108910)
38. Kim YM, Namkoong S, Yun YG, Hong HD, Lee YC, Ha KS, Lee H, Kwon HJ, Kwon YG, Kim YM,. Water extract of Korean red ginseng stimulates angiogenesis by activating the PI3K/Akt-dependent ERK1/2 and eNOS pathways in human umbilical vein endothelial cells. Biol Pharm Bull 2007; 30 (9): 1674-1679. (Pubitemid 47403243)
39. Mize GJ, Wang W, Takayama TK,. Prostate-specific kallikreins-2 and -4 enhance the proliferation of DU-145 prostate cancer cells through protease-activated receptors-1 and -2. Mol Cancer Res 2008; 6 (6): 1043-1051.
40. Liu E, Thant AA, Kikkawa F, Kurata H, Tanaka S, Nawa A, Mizutani S, Matsuda S, Hanafusa H, Hamaguchi M,. The ras-mitogen-activated protein kinase pathway is critical for the activation of matrix metalloproteinase secretion and the invasiveness in v-crk-transformed 3Y1. Cancer Res 2000; 60: 2361-2364. (Pubitemid 30262422)
41. Vayalil PK, Katiyar SK,. Treatment of epigallocatechin-3-gallate inhibits matrix metalloproteinases-2 and -9 via inhibition of activation of mitogen-activated protein kinases, c-jun and NF-kB in human prostate carcinoma DU-145 cells. Prostate 2004; 59: 33-42. (Pubitemid 38387841)